Patents Represented by Attorney, Agent or Law Firm Steven M. Odre
  • Patent number: 6723701
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: April 20, 2004
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Patent number: 6677136
    Abstract: The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: January 13, 2004
    Assignee: Amgen Inc.
    Inventors: William S. Marshall, Kevin Lee Stark
  • Patent number: 6660843
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: December 9, 2003
    Assignee: Amgen Inc.
    Inventors: Ulrich Feige, Chuan-Fa Liu
  • Patent number: 6589758
    Abstract: The invention relates to the three-dimensional structure of a crystal of a kinase enzyme complexed with a ligand. The three-dimensional structure of a protein kinase-ligand complex is disclosed. The invention also relates to methods of preparing such crystals. Kinase-ligand crystal structures wherein the ligand is an inhibitor molecule are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the invention also relates to methods of using the crystal structure of kinase enzyme-ligand complexes for identifying, designing, selecting, or testing inhibitors of kinase enzymes, such inhibitors being useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by kinases; having one or more kinase enzymes involved in their pathology.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: July 8, 2003
    Assignee: Amgen Inc.
    Inventor: Xiaotian Zhu
  • Patent number: 6583154
    Abstract: There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: June 24, 2003
    Assignee: Amgen Inc.
    Inventors: Mark Henry Norman, Clarence R. Hurt, Ning Chen, Christopher H. Fotsch, Nianhe Han, Tracy J. Jenkins, Longbin Liu, Ofir A. Moreno
  • Patent number: 6565841
    Abstract: Methods and compositions for pulmonary delivery of chemically modified G-CSF, and pegylated proteins are disclosed.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: May 20, 2003
    Assignee: Amgen, Inc.
    Inventors: Ralph Niven, Colin G Pitt
  • Patent number: 6552246
    Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: April 22, 2003
    Assignee: University Health Network
    Inventors: Tak Wah Mak, Josef Martin Penninger
  • Patent number: 6552170
    Abstract: Compounds are disclosed having the general formula R1-X-R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are TNF inhibitors.
    Type: Grant
    Filed: June 14, 1994
    Date of Patent: April 22, 2003
    Assignee: Amgen Inc.
    Inventors: Robert C. Thompson, Michael T. Brewer, Tadahiko Kohno
  • Patent number: 6514964
    Abstract: The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as &agr;v&bgr;3, &agr;v&bgr;5, &agr;v&bgr;6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: February 4, 2003
    Assignee: Amgen Inc.
    Inventors: Zhidong Chen, Celia Dominguez, Ellen Grenzer-Laber, Nianhe Han, Longbing Liu, Ofir A. Moreno, Melvin C. Rutledge, Andrew S. Tasker
  • Patent number: 6468970
    Abstract: The in vivo circulating life and/or absorption of Neurophic Factor-3 (NT-3) is increased by generating certain substitution analogs of the native protein sequence that result in a lower isoelectric point and charge in relation to NT-3 of native sequence.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: October 22, 2002
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Patent number: 6458813
    Abstract: Selected novel substituted pyridine compounds are effective for prophylaxis and treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: October 1, 2002
    Assignee: Amgen Inc.
    Inventors: Nathan B. Mantlo, Stephen T. Schlachter, John A. Josey
  • Patent number: 6455277
    Abstract: The present invention relates to glial cell line-derived neurotophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: September 24, 2002
    Assignee: Amgen Inc.
    Inventors: Gary M. Fox, Shuqian Jing, Duanzhi Wen
  • Patent number: 6455269
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of &agr;2-macroglobulin in the circulating blood.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: September 24, 2002
    Assignee: Amgen, Inc.
    Inventor: Christopher F. Toombs
  • Patent number: 6440973
    Abstract: The present invention comprises a new class of novel aryl and heteroaryl substituted fused pyrrole compounds useful for the prophylaxis and treatment of diseases or conditions, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of inflammation and other maladies, such as pain and diabetes, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: August 27, 2002
    Assignee: Amgen Inc.
    Inventors: Jeffery A. Zablocki, Eugene Tarlton, Jr., James P. Rizzi, Nathan B. Mantlo
  • Patent number: 6432449
    Abstract: The present invention relates to sustained-release formulations using biodegradable alginate delayed gels or particles and methods thereof.
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: August 13, 2002
    Assignee: Amgen Inc.
    Inventors: Merrill Seymour Goldenberg, Jian Hua Gu
  • Patent number: 6420339
    Abstract: The present invention relates generally to the chemical modification of biologically active agents. More, specifically, the invention relates to a novel approach to engineer, through mutagenesis and site-directed chemical conjugation, specific, well-defined dualPEGylated-protein bioconjugates, consisting of two polyethylene glycol (PEG) macromolecules chemically conjugated to the protein at two specifically defined amino acid residues. The described dualPEGylated-protein bioconjugates show substantially improved bioefficacy and biocompatibility.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: July 16, 2002
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Patent number: 6420340
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: July 16, 2002
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Patent number: 6369202
    Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: April 9, 2002
    Assignee: Amgen Canada Inc.
    Inventors: Toshifumi Matsuyama, Alex Grossman, Christopher Donald Richardson
  • Patent number: 6369027
    Abstract: The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: September 3, 1996
    Date of Patent: April 9, 2002
    Assignee: Amgen Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • Patent number: 6365050
    Abstract: An improved flow field-flow fractionation (flow FFF) process has been developed which permits the high-resolution separation of analytes without stopping or reversing the axial flow, introducing additional axial flow streams, or further splitting the axial flow stream. The improved procedure speeds up, streamlines, and simplifies the apparatus and the procedure without unduly concentrating the sample, permits the use of flow-sensitive detection technologies in a manner which has previously been difficult or impossible, and avoids the artifactual aggregation which is known to result from other relaxation procedures. The process also permits the calculation of the channel width w without reference to system or void peaks in the fractogram. These capabilities render the improved flow FFF procedure more accurate as well as more practical, and permit automated flow FFF separations to be routinely performed on commercially-available HPLC systems with only minor modifications.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: April 2, 2002
    Assignee: Amgen Inc.
    Inventor: Gregory Paul Cauchon